Comparative Pharmacology
Head-to-head clinical analysis: BYSTOLIC versus INDERIDE LA 160 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BYSTOLIC versus INDERIDE LA 160 50.
BYSTOLIC vs INDERIDE LA 160/50
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bystolic (nebivolol) is a beta-1 selective adrenergic receptor antagonist with additional nitric oxide-mediated vasodilatory effects. It decreases heart rate, myocardial contractility, and blood pressure by blocking beta-1 receptors in the heart and kidney, and enhances nitric oxide release from vascular endothelium via beta-3 receptor activation.
Propranolol: Non-selective beta-adrenergic receptor antagonist (blocks β1 and β2 receptors). Hydrochlorothiazide: Thiazide diuretic inhibiting Na+/Cl- cotransporter in distal convoluted tubule, reducing intravascular volume by increasing sodium and water excretion.
Oral: 5 mg once daily; may increase at 2-week intervals to 10 mg, 20 mg, 40 mg; maximum 40 mg/day.
One capsule orally once daily. Each capsule contains propranolol hydrochloride 160 mg and hydrochlorothiazide 50 mg. Dosage should be individualized; typical maintenance dose is 1 capsule per day.
None Documented
None Documented
Terminal elimination half-life: 10-12 hours; allows once-daily dosing in most patients; steady-state achieved in 3-5 days
Propranolol: 3-6 hours (parent drug), 8-12 hours (4-hydroxypropranolol active metabolite) with prolonged half-life in hepatic impairment; Hydrochlorothiazide: 6-15 hours, extended in renal impairment (creatinine clearance <30 mL/min).
Renal: 38% unchanged; hepatic metabolism: extensive; fecal: minor; total renal clearance accounts for 30-50% of dose
Propranolol: primarily hepatic metabolism to inactive metabolites, <1% excreted unchanged in urine; Hydrochlorothiazide: 50-70% excreted unchanged in urine, remainder as metabolites via renal and biliary routes.
Category C
Category C
Beta Blocker
Beta Blocker